MX2023005179A - Proteínas de unión que reconocen antígeno ha-1 y usos de las mismas. - Google Patents

Proteínas de unión que reconocen antígeno ha-1 y usos de las mismas.

Info

Publication number
MX2023005179A
MX2023005179A MX2023005179A MX2023005179A MX2023005179A MX 2023005179 A MX2023005179 A MX 2023005179A MX 2023005179 A MX2023005179 A MX 2023005179A MX 2023005179 A MX2023005179 A MX 2023005179A MX 2023005179 A MX2023005179 A MX 2023005179A
Authority
MX
Mexico
Prior art keywords
antigen
binding proteins
proteins recognizing
recognizing
recognize
Prior art date
Application number
MX2023005179A
Other languages
English (en)
Spanish (es)
Inventor
Ribhu Nayar
Gavin Macbeath
Sonal Jangalwe
Mollie M Jurewicz
Andrew S Basinski
Qikai Xu
Antoine J Boudot
Tomasz Kula
Original Assignee
Tscan Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tscan Therapeutics Inc filed Critical Tscan Therapeutics Inc
Publication of MX2023005179A publication Critical patent/MX2023005179A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
MX2023005179A 2020-11-06 2021-11-08 Proteínas de unión que reconocen antígeno ha-1 y usos de las mismas. MX2023005179A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063110851P 2020-11-06 2020-11-06
US202063111462P 2020-11-09 2020-11-09
US202063129804P 2020-12-23 2020-12-23
US202163175350P 2021-04-15 2021-04-15
PCT/US2021/058382 WO2022099100A2 (en) 2020-11-06 2021-11-08 Binding proteins recognizing ha-1 antigen and uses thereof

Publications (1)

Publication Number Publication Date
MX2023005179A true MX2023005179A (es) 2023-07-13

Family

ID=81458633

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005179A MX2023005179A (es) 2020-11-06 2021-11-08 Proteínas de unión que reconocen antígeno ha-1 y usos de las mismas.

Country Status (10)

Country Link
US (1) US20230398217A1 (cg-RX-API-DMAC7.html)
EP (1) EP4240490A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023549765A (cg-RX-API-DMAC7.html)
KR (1) KR20230117576A (cg-RX-API-DMAC7.html)
AU (3) AU2021323388C1 (cg-RX-API-DMAC7.html)
CA (1) CA3197255A1 (cg-RX-API-DMAC7.html)
IL (1) IL302616A (cg-RX-API-DMAC7.html)
MX (1) MX2023005179A (cg-RX-API-DMAC7.html)
TW (1) TW202227499A (cg-RX-API-DMAC7.html)
WO (1) WO2022099100A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024130009A1 (en) * 2022-12-14 2024-06-20 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers
WO2025217028A1 (en) * 2024-04-08 2025-10-16 Tscan Therapeutics, Inc. Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
WO2025217035A2 (en) * 2024-04-08 2025-10-16 Tscan Therapeutics, Inc. Use of anti-ha-1 and anti-ha-2 binding proteins for treatment of aml, all, and mds
WO2025231299A1 (en) * 2024-05-02 2025-11-06 Fred Hutchinson Cancer Center Tcr t cell therapy targeting ha-1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013535199A (ja) * 2010-07-28 2013-09-12 イムノコア リミテッド T細胞レセプター
KR102397771B1 (ko) * 2016-09-23 2022-05-13 프레드 헛친슨 켄서 리서치 센터 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도
WO2020030631A1 (en) * 2018-08-06 2020-02-13 Medigene Immunotherapies Gmbh Ha-1 specific t cell receptors and their use
NL2021789B1 (en) * 2018-10-10 2020-05-14 Academisch Ziekenhuis Leiden Binding proteins specific for HA-1H and uses thereof

Also Published As

Publication number Publication date
IL302616A (en) 2023-07-01
JP2023549765A (ja) 2023-11-29
KR20230117576A (ko) 2023-08-08
AU2026200575A1 (en) 2026-02-19
CA3197255A1 (en) 2022-05-12
EP4240490A4 (en) 2025-06-18
TW202227499A (zh) 2022-07-16
WO2022099100A2 (en) 2022-05-12
AU2021323388B2 (en) 2022-07-28
WO2022099100A3 (en) 2022-06-16
US20230398217A1 (en) 2023-12-14
AU2021323388A1 (en) 2022-05-26
AU2022241563A1 (en) 2022-11-03
EP4240490A2 (en) 2023-09-13
AU2022241563B2 (en) 2025-11-27
AU2021323388C1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
MX2020003125A (es) Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
ECSP18095014A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
MX2020009568A (es) Anticuerpos que se unen a cd39 y sus usos.
MX2021006237A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
CL2020003391A1 (es) Proteína de unión al antígeno anti-steap1
CL2021003580A1 (es) Compuestos que comprenden un ligando de proteína de activación de fibroblastos y su uso
CO2019005966A2 (es) Esteroides y conjugados de proteínas de los mismos
EP3903447A4 (en) AUTOMATIC VEHICLE IDENTITY VERIFICATION AND VEHICLE PRESENCE VALIDATION
MX2020001879A (es) Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
CY1124272T1 (el) Κατασκευασματα παραλλαγης sirp-αλφα και χρησεις αυτων
DOP2020000236A (es) Anticuerpos il-1 1ra
BR112018012388A2 (pt) imunoglobulinas conjugadas de lisina terminal-c
BR112023021034A2 (pt) Proteínas de ligação que reconhecem antígeno ha-2 e usos dos mesmos
MA52626A (fr) Anticorps anti-cd63, conjugués et leurs utilisations
IL281076A (en) Anti-cd3 antibody folate bioconjugates and their uses
PE20230381A1 (es) Proteina de union a rgma
BR112023015050A2 (pt) Anticorpos anti-met e usos dos mesmos
CO2024007117A2 (es) Proteínas de unión que reconocen al antígeno hpv16 e7 y usos de las mismas
CO2024007212A2 (es) Péptidos inmunogénicos magea1, proteínas de unión que reconocen péptidos inmunogénicos magea1, y usos de estos
WO2022099100A3 (en) Binding proteins recognizing ha-1 antigen and uses thereof
BR112023021162A2 (pt) Peptídeos imunogênicos de magec2, proteínas de ligação que reconhecem os peptídeos imunogênicos de magec2 e usos dos mesmos
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
LT3886914T (lt) Antikūnas, apimantis lengvosios grandinės c gale esantį glutamino turintį prailginimą, jo konjugatus ir metodus bei panaudojimo būdus
MX2025004002A (es) Peptidos inmunogenicos prame, proteinas de union que reconocen los peptidos inmunogenicos prame y usos de los mismos
CL2025000397A1 (es) Moléculas de unión a d3 y usos de estas